Breaking News, Collaborations & Alliances

Cellumed and ARTES Sign Development and License Agreement

Accelerate development of GMP-grade production enzymes essential for manufacturing mRNA-based biopharmaceuticals.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Cellumed Co. Ltd., based in Seoul, Korea, and Germany-based ARTES Biotechnology GmbH have entered a development and license agreement aiming at the generation of microbial production cell lines, processes and documentation for the cGMP manufacturing of two enzymes required in the manufacturing process of mRNA vaccines.   Under this agreement, ARTES will be responsible for the development of high yield microbial cell lines expressing two recombinant enzymes. Further steps at ARTES will include th...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters